Expression profile of microRNAs in c-Myc induced mouse mammary tumors

Abstractc-Myc is a transcription factor overexpression of which induces mammary cancer in transgenic mice. To explore whether certain microRNAs (mirRNA) mediate c-Myc induced mammary carcinogenesis, we studied mirRNA expression profile in mammary tumors developed from MMTV-c-myc transgenic mice, and found 50 and 59 mirRNAs showing increased and decreased expression, respectively, compared with lactating mammary glands of wild type mice. Twenty-four of these mirRNAs could be grouped into eight clusters because they had the same chromosomal localizations and might be processed from the same primary RNA transcripts. The increased expression of mir-20a, mir-20b, and mir-9 as well as decreased expression of mir-222 were verified by RT-PCR, real-time RT-PCR, and cDNA sequencing. Moreover, we fortuitously identified a novel non-coding RNA, the level of which was decreased in proliferating mammary glands of MMTV-c-myc mice was further decreased to undetectable level in the mammary tumors. Sequencing of this novel RNA revealed that it was transcribed from a region of mouse chromosome 19 that harbored the metastasis associated lung adenocarcinoma transcript-1 (Malat-1), a non-protein-coding gene. These results suggest that certain mirRNAs and the chromosome 19 derived non-coding RNAs may mediate c-myc induced mammary carcinogenesis.

[1]  C. Croce,et al.  Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[2]  K. Livak,et al.  Multiplexing RT-PCR for the detection of multiple miRNA species in small samples. , 2006, Biochemical and biophysical research communications.

[3]  P. Knoepfler.  Myc goes global: new tricks for an old oncogene. , 2007, Cancer research.

[4]  C. Arenz,et al.  MicroRNAs--future drug targets? , 2006, Angewandte Chemie.

[5]  S. Balcerzak,et al.  Characterization of the 5q- breakpoint in an acute nonlymphocytic leukemia patient using pulsed-field gel electrophoresis. , 1991, American journal of medical genetics.

[6]  K Fenwick,et al.  Array CGH profiling of favourable histology Wilms tumours reveals novel gains and losses associated with relapse , 2006, The Journal of pathology.

[7]  David I. Smith,et al.  Long, abundantly expressed non-coding transcripts are altered in cancer. , 2008, Human molecular genetics.

[8]  H. Horvitz,et al.  MicroRNA expression profiles classify human cancers , 2005, Nature.

[9]  A. Berchuck,et al.  Loss of heterozygosity at chromosome segment Xq25‐26.1 in advanced human ovarian carcinomas , 1997, Genes, chromosomes & cancer.

[10]  C. Sotiriou,et al.  BRCA1-mediated repression of select X chromosome genes , 2004, Journal of Translational Medicine.

[11]  C. Croce,et al.  MicroRNA gene expression deregulation in human breast cancer. , 2005, Cancer research.

[12]  Zhiping Weng,et al.  Global mapping of c-Myc binding sites and target gene networks in human B cells , 2006, Proceedings of the National Academy of Sciences.

[13]  林下 陽二.  A polycistronic microRNA cluster, miR-17-92, is overexpressed in human lung cancers and enhances cell proliferation , 2006 .

[14]  M. Sasiadek,et al.  Three distinct regions of deletion on 13q in squamous cell carcinoma of the larynx. , 2006, Oncology reports.

[15]  D. Grignon,et al.  Histological complexities of pancreatic lesions from transgenic mouse models are consistent with biological and morphological heterogeneity of human pancreatic cancer. , 2007, Histology and histopathology.

[16]  S. Roychoudhury,et al.  Deletion mapping of chromosome 13q in head and neck squamous cell carcinoma in Indian patients: correlation with prognosis of the tumour , 2006, International journal of experimental pathology.

[17]  D. Liao,et al.  Molecular Cancer Gene Expression Profiles in Primary Pancreatic Tumors and Metastatic Lesions of Ela-c-myc Transgenic Mice , 2008 .

[18]  Birgit Samans,et al.  MYCN regulates oncogenic MicroRNAs in neuroblastoma , 2007, International journal of cancer.

[19]  C. Croce,et al.  A microRNA expression signature of human solid tumors defines cancer gene targets , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[20]  Perspective: prostate cancer susceptibility genes. , 2002, Endocrinology.

[21]  J. Filmus,et al.  Glypicans in growth control and cancer. , 2001, Glycobiology.

[22]  C. V. Jongeneel,et al.  Identification of cancer/testis-antigen genes by massively parallel signature sequencing , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[23]  D. Liao,et al.  c-Myc in breast cancer. , 2000, Endocrine-related cancer.

[24]  H. Ropers,et al.  Cloning and characterization of UXT, a novel gene in human Xp11, which is widely and abundantly expressed in tumor tissue. , 1999, Genomics.

[25]  Å. Borg,et al.  Chromosome 5 imbalance mapping in breast tumors from BRCA1 and BRCA2 mutation carriers and sporadic breast tumors , 2006, International journal of cancer.

[26]  T Takahashi,et al.  Apoptosis induction by antisense oligonucleotides against miR-17-5p and miR-20a in lung cancers overexpressing miR-17-92 , 2007, Oncogene.

[27]  Stijn van Dongen,et al.  miRBase: microRNA sequences, targets and gene nomenclature , 2005, Nucleic Acids Res..

[28]  H. Taubert,et al.  Gains of 13q are correlated with a poor prognosis in liposarcoma , 2005, Modern Pathology.

[29]  J. Yates,et al.  A role for the P-body component GW182 in microRNA function , 2005, Nature Cell Biology.

[30]  Tsung-Cheng Chang,et al.  Widespread microRNA repression by Myc contributes to tumorigenesis , 2008, Nature Genetics.

[31]  Anwar Hossain,et al.  Mir-17-5p Regulates Breast Cancer Cell Proliferation by Inhibiting Translation of AIB1 mRNA , 2006, Molecular and Cellular Biology.

[32]  A. Monaco,et al.  The t(X;18)(p11.2;q11.2) translocation found in human synovial sarcomas involves two distinct loci on the X chromosome. , 1994, Oncogene.

[33]  T A Hughes,et al.  Small is beautiful: microRNAs and breast cancer—where are we now? , 2008, The Journal of pathology.

[34]  Chun Xing Li,et al.  Differential expression of components of the microRNA machinery during mouse organogenesis. , 2005, Biochemical and biophysical research communications.

[35]  S. Seal,et al.  Localization to Xq27 of a susceptibility gene for testicular germ-cell tumours , 2000, Nature Genetics.

[36]  C. Cooper,et al.  Mapping the X chromosome breakpoint in two papillary renal cell carcinoma cell lines with a t(X;1)(p11.2;q21.2) and the first report of a female case. , 1995, Cytogenetics and cell genetics.

[37]  Thomas Tuschl,et al.  The growing catalog of small RNAs and their association with distinct Argonaute/Piwi family members , 2008, Development.

[38]  Tara L. Naylor,et al.  microRNAs exhibit high frequency genomic alterations in human cancer. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[39]  Richard W. Carthew,et al.  Silence from within: Endogenous siRNAs and miRNAs , 2005, Cell.

[40]  P. Kapur,et al.  Pediatric Renal Cell Carcinomas with Xp11.2 Rearrangements Are Immunoreactive for hMLH1 and hMSH2 Proteins , 2005, Pediatric and developmental pathology : the official journal of the Society for Pediatric Pathology and the Paediatric Pathology Society.

[41]  S. Lowe,et al.  A microRNA polycistron as a potential human oncogene , 2005, Nature.

[42]  K. Arden,et al.  Identification of a new MAGE gene with tumor-specific expression by representational difference analysis. , 1998, Cancer research.

[43]  Hiroyuki Tagawa,et al.  Identification and characterization of a novel gene, C13orf25, as a target for 13q31-q32 amplification in malignant lymphoma. , 2004, Cancer research.

[44]  O. Kovalchuk,et al.  Estrogen-Induced Rat Breast Carcinogenesis is Characterized by Alterations in DNA Methylation, Histone Modifications, and Aberrant microRNA Expression , 2007, Cell cycle.

[45]  D. Pinkel,et al.  Genomic Alterations in Primary Gastric Adenocarcinomas Correlate with Clinicopathological Characteristics and Survival , 2004, Cellular oncology : the official journal of the International Society for Cellular Oncology.

[46]  K. Yanagisawa,et al.  Identification of hypoxia-inducible factor-1 alpha as a novel target for miR-17-92 microRNA cluster. , 2008, Cancer research.

[47]  W. J. Brammar,et al.  Loss of heterozygosity on the X chromosome in human breast cancer , 1995, Genes, chromosomes & cancer.

[48]  J. Rowley,et al.  Assignment of CSF-1 to 5q33.1: evidence for clustering of genes regulating hematopoiesis and for their involvement in the deletion of the long arm of chromosome 5 in myeloid disorders. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[49]  C. Croce,et al.  MicroRNA-cancer connection: the beginning of a new tale. , 2006, Cancer research.

[50]  Hong Jiang,et al.  A novel method to monitor the expression of microRNAs , 2006, Molecular biotechnology.

[51]  F. Sarkar,et al.  Perspectives on c-Myc, Cyclin D1, and their interaction in cancer formation, progression, and response to chemotherapy. , 2007, Critical reviews in oncogenesis.

[52]  Phillip D. Zamore,et al.  Ribo-gnome: The Big World of Small RNAs , 2005, Science.

[53]  S. Juhng,et al.  Loss of heterozygosity on chromosome XP22.2-p22.13 and Xq26.1-q27.1 in human breast carcinomas. , 1998, Journal of Korean medical science.

[54]  D. Levens,et al.  c-myc expression: keep the noise down! , 2005, Molecules and cells.

[55]  U. Weidle,et al.  The XAGE family of cancer/testis‐associated genes: Alignment and expression profile in normal tissues, melanoma lesions and Ewing's sarcoma , 2002, International journal of cancer.

[56]  Tanya M. Teslovich,et al.  Physical and transcript map of the hereditary prostate cancer region at xq27. , 2002, Genomics.

[57]  Toshiro Ono,et al.  Identification and characterization of mouse SSX genes: a multigene family on the X chromosome with restricted cancer/testis expression. , 2003, Genomics.

[58]  Kathryn A. O’Donnell,et al.  c-Myc-regulated microRNAs modulate E2F1 expression , 2005, Nature.

[59]  J. Brooks.  Common sequence variants on 2p15 and Xp11.22 confer susceptibility to prostate cancer , 2008 .

[60]  S. Law,et al.  Identification of a novel tumor transforming gene GAEC1 at 7q22 which encodes a nuclear protein and is frequently amplified and overexpressed in esophageal squamous cell carcinoma , 2007, Oncogene.

[61]  C. Croce,et al.  MicroRNA genes are frequently located near mouse cancer susceptibility loci , 2007, Proceedings of the National Academy of Sciences.

[62]  D. Grignon,et al.  Novel Perspective: Focusing on the X Chromosome in Reproductive Cancers , 2003, Cancer investigation.

[63]  S. Hirohashi,et al.  Identification of SMURF1 as a possible target for 7q21.3‐22.1 amplification detected in a pancreatic cancer cell line by in‐house array‐based comparative genomic hybridization , 2008, Cancer science.

[64]  Kenneth J Livak,et al.  Real time PCR profiling of 330 human micro‐RNAs , 2007, Biotechnology journal.

[65]  P. Terpstra,et al.  An evolutionary rearrangement of the Xp11.3-11.23 region in 3p21.3, a region frequently deleted in a variety of cancers. , 1999, Genomics.

[66]  J. Inazawa,et al.  GPC5 is a possible target for the 13q31-q32 amplification detected in lymphoma cell lines , 2003, Journal of Human Genetics.